Patents by Inventor James Ranger-Moore

James Ranger-Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170082627
    Abstract: Disclosed herein are methods for predicting the response to a HER2-directed therapy and for scoring a breast cancer tumor sample. In some embodiments, the methods include contacting the sample with an antibody that specifically binds HER2 protein and detecting presence and/or amount of HER2 protein and contacting the sample with a nucleic acid probe that specifically binds to HER2 genomic DNA and detecting presence and/or amount of HER2 genomic DNA (such as HER2 gene copy number). In some embodiments, the methods further include detection of a centromere nucleic acid (such as chromosome 17 centromere DNA) and contacting the sample with an antibody that specifically binds ER protein and detecting presence and/or amount of ER protein in the same sample.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Eslie Dennis, Masafumi Kurosumi, Sasagu Kurozumi, Hiro Nitta, Mary Padilla, James Ranger-Moore
  • Publication number: 20130115628
    Abstract: The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.
    Type: Application
    Filed: August 2, 2012
    Publication date: May 9, 2013
    Applicants: VENTANA MEDICAL SYSTEMS, INC., CLOVIS ONCOLOGY, INC.
    Inventors: Jeffrey Dean Isaacson, Mical Raponi, James Ranger-Moore, Eric L. Powell
  • Publication number: 20130116209
    Abstract: The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.
    Type: Application
    Filed: August 2, 2012
    Publication date: May 9, 2013
    Applicants: VENTANA MEDICAL SYSTEMS, INC., CLOVIS ONCOLOGY, INC.
    Inventors: Jeffrey Dean Isaacson, Mical Raponi, James Ranger-Moore, Eric L. Powell
  • Publication number: 20120141472
    Abstract: Disclosed herein are methods of predicting prognosis of a neoplastic disease (such as lung cancer, for example NSCLC), including determining the IGF1R gene copy number in a biological sample from a patient having a neoplastic disease; wherein an increase in IGF1R copy number predicts a good prognosis of the neoplastic disease in the patient. Also disclosed herein are methods of scoring copy number of a gene of interest in a biological sample. The method includes identifying individual cells in the sample having highest number of signals for the gene of interest detected by in situ hybridization, counting the number of signals for the gene of interest in the identified individual cells and determining an average number of signals per cell.
    Type: Application
    Filed: May 28, 2010
    Publication date: June 7, 2012
    Inventors: Shalini Singh, Fabien Gaire, James Ranger-Moore